이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Neuren Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

Neuren Pharmaceuticals 의 총 주주 지분은 A$205.2M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$248.0M 및 A$42.8M 입니다. Neuren Pharmaceuticals 의 EBIT는 A$199.2M 이며 이자보상배율은 -35 입니다. A$228.5M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	-35x
현금	AU$228.54m
주식	AU$205.21m
총 부채	AU$42.76m
총 자산	AU$247.97m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: NEU 의 단기 자산 ( A$247.2M )이 단기 부채( A$42.8M ).

장기 부채: NEU 에는 장기 부채가 없습니다.

부채 대 자본 내역 및 분석

부채 수준: NEU 부채가 없습니다.

부채 감소: NEU 지난 5년간 부채가 없습니다.

부채 범위: NEU 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: NEU 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Neuren Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Investor sentiment improves as stock rises 16%

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Investor sentiment improves as stock rises 38%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 25% undervalued after recent price drop

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Independent Non-Executive Director recently sold AU$15m worth of stock

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Independent Non-Executive Director recently bought AU$59k worth of stock

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

High number of new directors

Independent Non-Executive Chairman recently bought AU$61k worth of stock

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

New 90-day low: AU$1.26

Full year 2020 earnings released: AU$0.086 loss per share (vs AU$0.11 loss in FY 2019)

Independent Non-Executive Chairman recently bought AU$50k worth of stock

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

New 90-day high: AU$1.40

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

New 90-day high: AU$1.30

New 90-day low: AU$1.06

New 90-day low: AU$1.10

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기